Project Number 5R37AG011385-16 Agency/Funding Organization NIA Funding Year 2009 View Full Project Details for TRANSGENIC MODELS TO STUDY ALZHEIMER'S DISEASE Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 4. ApoE and Lipid Neurobiology a. ApoE in Abeta-Mediated AD Pathogenesis Category F. Research Resources 6. Disease Models c. Rodents Researcher and Organization Principal Investigator MUCKE, LENNART Principal Investigator First Name LENNART Principal Investigator Last Name MUCKE Awardee Organization J. DAVID GLADSTONE INSTITUTES Awardee State California Contact PI Country United States Project Detail FY Overall Cost $483,286 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official REFOLO, LORENZO Related Resources Repository [AlzPED] Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease [AlzPED] Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model [AlzPED] Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. Patent Methods of treating neurodegenerative disease Agents that reduce neuronal overexcitation Transgenic mouse model for neurodegenerative diseases Methods of detecting neurological disorders Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy Transgenic mice expressing human APP and TGF-.beta. demonstrate cerebrovascular amyloid deposits
